Karl Ecklund, left, and Paul Padley of Rice University have received a $1.3 million grant from the Department of Energy to continue physics research on the universe. Photo by Jeff Fitlow/Rice University

Two Rice University physicists and professors have received a federal grant to continue research on dark matter in the universe.

Paul Padley and Karl Ecklund, professors of physics and astronomy at Rice, have received a $1.3 million grant from the Department of Energy to continue the university's ongoing research at the Large Hadron Collider, or LHC, a particle accelerator consisting of a 17-mile ring of superconducting magnets buried beneath Switzerland and France.

"With this grant we will be able to continue our investigations into the nature of the matter that comprises the universe, what the dark matter that permeates the universe is, and if there is physics beyond what we already know," Padley says in a press release.

This grant is a part of the DOE's $132 million in funding for high-energy physics research. The LHC has received a total of $4.5 million to date to continue this research. Most recently, Ecklund and Padley received a $3 million National Science Foundation grant to go toward updates to the LHC.

"High-energy physics research improves our understanding of the universe and is an essential element for maintaining America's leadership in science," says Paul Dabbar, undersecretary for science at the DOE, in the release. "These projects at 53 different institutions across our nation will advance efforts both in theory and through experiments that explore the subatomic world and study the cosmos. They will also support American scientists serving key roles in important international collaborations at institutions across our nation."

In 2012, Padley and his team discovered the Higgs boson, a feat that was extremely key to the continuance of exploring the Standard Model of particle physics. Since then, the physicists have been working hard to answer the many questions involved in studying physics and the universe.

"Over many decades, the particle physics group at Rice has been making fundamental contributions to our understanding of the basic building blocks of the universe," Padley says in the release. "With this grant we will be able to continue this long tradition of important work."

Paul Padley and his team as made important dark matter findings at the Large Hadron Collider in Europe. Photo via rice.ed

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”